Moderna
MRNA
717 hedge funds and large institutions have $20.9B invested in Moderna in 2020 Q4 according to their latest regulatory filings, with 228 funds opening new positions, 235 increasing their positions, 189 reducing their positions, and 50 closing their positions.
356% more first-time investments, than exits
New positions opened: 228 | Existing positions closed: 50
44% more capital invested
Capital invested by funds: $14.5B → $20.9B (+$6.43B)
31% more funds holding
Funds holding: 547 → 717 (+170)
30% more funds holding in top 10
Funds holding in top 10: 10 → 13 (+3)
24% more repeat investments, than reductions
Existing positions increased: 235 | Existing positions reduced: 189
1.5% less ownership
Funds ownership: 51.99% → 50.49% (-1.5%)
24% less call options, than puts
Call options by funds: $1.52B | Put options by funds: $2B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$1.73B |
| 2 |
D.E. Shaw & Co
New York
|
+$237M |
| 3 |
Renaissance Technologies
New York
|
+$177M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$108M |
| 5 |
Two Sigma Investments
New York
|
+$82.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.66B |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$456M |
| 3 |
TP
Theleme Partners
London,
United Kingdom
|
-$234M |
| 4 |
FT
Fiduciary Trust
Boston,
Massachusetts
|
-$83.1M |
| 5 |
AII
AGF Investments Inc
Toronto,
Ontario, Canada
|
-$71.6M |
MRNA Hedge Fund Activity: Q4 2020 in Review
717 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Moderna (MRNA) for Q4 2020, worth a combined $20.9B — up 44% from $14.5B a quarter earlier.
Buyers outnumbered sellers: 228 funds opened new MRNA positions and 50 closed out — a net gain of 178 holders — while 235 added to existing stakes and 189 trimmed.
The largest buyer was Baillie Gifford & Co, adding an estimated $1.73B. The largest seller was Fidelity Investments, cutting an estimated $2.66B.
- 717 institutional investors held Moderna (MRNA) as of Q4 2020, up from 547 in Q3 2020.
- Funds reported $20.9B of Moderna stock for Q4 2020, up 44% quarter-over-quarter.
- 228 funds opened new Moderna positions in Q4 2020 and 50 closed out, a net change of +178 holders.
- The largest Moderna buyer in Q4 2020 was Baillie Gifford & Co, an estimated $1.73B added.
- The largest Moderna seller in Q4 2020 was Fidelity Investments, an estimated $2.66B sold.
Based on aggregated 13F filings for Q4 2020.